Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology
- S. Alexander, R. Roberts, A. Ahluwalia
- BiologyBritish Journal of Pharmacology
- 1 February 2018
The aim of this article is to outline the rationale for, and the expectations of, the BJP with respect to work published in the Journal that includes immunoblotting or immunohistochemical data and to reduce potential misinterpretations and to maximise the communication and transparency of essential information.
Experimental design and analysis and their reporting: new guidance for publication in BJP
- M. Curtis, R. Bond, J. McGrath
- Computer ScienceBritish Journal of Pharmacology
- 26 June 2015
This Editorial is part of a series of editorials based on research published in The Lancet Onlinelibrary.wiley.com/doi/10.1111/bph.13112/abstract.
Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
- M. Curtis, S. Alexander, A. Ahluwalia
- MedicineBritish Journal of Pharmacology
- 1 April 2018
The guidelines have been simplified for ease of understanding by authors, to make it more straightforward for peer reviewers to check compliance and to facilitate the curation of the journal's efforts to improve standards.
Pharmacology of the eosinophil.
- M. Giembycz, M. Lindsay
- MedicinePharmacological Reviews
- 1 June 1999
Prostanoid receptor antagonists: development strategies and therapeutic applications
- Rl Jones, M. Giembycz, D. Woodward
- Biology, MedicineBritish Journal of Pharmacology
- 1 September 2009
This review is intended to provide overviews of each antagonist class (including prostamide antagonists), covering major development strategies and current and potential clinical usage.
Protein kinase C isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis
- B. Webb, S. Hirst, M. Giembycz
- BiologyBritish Journal of Pharmacology
- 1 August 2000
The organization and regulation of PKC are described and the current understanding of their role in the regulation of airways smooth muscle (ASM) tone and mitogenesis is reviewed, which have been investigated in some detail.
Release of granulocyte‐macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone
- M. Saunders, J. Mitchell, M. Belvisi
- Biology, MedicineBritish Journal of Pharmacology
- 1 February 1997
The data suggest that human airway smooth muscle cells might play an active part in initiating and/or perpetuating airway inflammation in addition to controlling airway calibre.
Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T‐lymphocytes: role in regulating proliferation and the biosynthesis of interleukin‐2
- M. Giembycz, C. Corrigan, J. Seybold, R. Newton, P. Barnes
- Biology, MedicineBritish Journal of Pharmacology
- 1 August 1996
The ability of rolipram to suppress markedly mitogen‐induced IL‐2 generation without affecting T‐cell proliferation suggests that growth and division of T‐lymphocytes may be governed by mediators in addition to IL‐ 2.
Differential Regulation of Cytokine Release and Leukocyte Migration by Lipopolysaccharide-Stimulated Primary Human Lung Alveolar Type II Epithelial Cells and Macrophages1
- A. Thorley, P. Ford, M. Giembycz, P. Goldstraw, A. Young, T. Tetley
- Biology, MedicineJournal of Immunology
- 1 January 2007
Activated alveolar epithelium is an important source of chemokines that orchestrate leukocyte migration to the peripheral lung; early release of TNF-α and IL-1β by stimulated macrophages may contribute to alveolars epithelial cell activation and chemokine production.
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
- M. Giembycz
- Medicine, BiologyExpert Opinion on Investigational Drugs
- 1 July 2001
Cilomilast displays a promising clinical profile in the treatment of inflammatory airway diseases, in particular COPD and the results of further Phase III trials are awaited with interest.
...
...